{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:53:33Z","timestamp":1777730013948,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Die Detektion klinisch signifikanter Prostatakarzinome bleibt eine diagnostische Herausforderung. Die Kombination aus MRT-Fusionsbiopsie und systematischer Biopsie gilt als Standard in der Prim\u00e4rdiagnostik.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>Untersucht wurden Unterschiede in den leitliniengerechten Therapieempfehlungen basierend auf der Histologie der MRT-Fusions- bzw. systematischen Biopsie sowie deren \u00dcbereinstimmung mit der Resektathistologie.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methoden<\/jats:title>\n                    <jats:p>\n                      Eingeschlossen wurden 476\u00a0Patienten mit Prostatabiopsie zwischen Januar 2022 und Dezember 2024. Prim\u00e4re Endpunkte waren die histologischen Ergebnisse je Biopsiemethode und die daraus abgeleiteten Therapieempfehlungen. In einer Subgruppe von 57\u00a0Patienten (115\u00a0L\u00e4sionen) mit radikaler Prostatektomie wurde die \u00dcbereinstimmung zwischen Biopsie- und Resektathistologie in Abh\u00e4ngigkeit vom PI-RADS-Score analysiert. Die Auswertung erfolgte mittels Binomialtest, McNemar-Test, Cohens Kappa und logistischer Regression (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090,05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>\n                      Das kombinierte Verfahren detektierte signifikant mehr klinisch relevante Karzinome als die systematische Biopsie (41,7\u202f% vs.\u00a027,9\u202f%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090,001) und f\u00fchrte h\u00e4ufiger zu kurativen Therapieempfehlungen (36,0\u202f% vs.\u00a026,2\u202f%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090,001). Auch gegen\u00fcber der MRT-Fusionsbiopsie allein war die Rate kurativer Empfehlungen h\u00f6her (36,0\u202f% vs.\u00a032,8\u202f%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090,001). Die \u00dcbereinstimmung des Gleason-Scores mit dem Resektat war bei PI-RADS-5-L\u00e4sionen am h\u00f6chsten (\u03ba\u202f=\u20090,294) und signifikant h\u00f6her als bei PI-RADS\u20113 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090,029).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Das kombinierte Biopsieverfahren erh\u00f6ht die Rate leitliniengerechter kurativer Therapieempfehlungen. Der zus\u00e4tzliche Nutzen der systematischen Biopsie bleibt jedoch gering. Ein h\u00f6herer \u00dcbereinstimmungsgrad zwischen Biopsie- und Resektathistologie zeigte sich nur bei PI-RADS-5-L\u00e4sionen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00120-025-02738-8","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:09:23Z","timestamp":1765278563000},"page":"513-520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Einfluss der MRT-Fusionsbiopsie auf Therapieempfehlungen","Influence of MRI fusion biopsy on treatment recommendations"],"prefix":"10.1007","volume":"65","author":[{"given":"P.","family":"Schildhauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"F\u00fcrschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Elser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Moderegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. E.","family":"Fender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2738_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot\u00a0M, Wilbur\u00a0AR, Reese\u00a0SE, Lebastchi\u00a0AH, Mehralivand\u00a0S, Gomella\u00a0PT, Bloom\u00a0J, Gurram\u00a0S, Siddiqui\u00a0M, Pinsky\u00a0P, Parnes\u00a0H, Linehan\u00a0WM, Merino\u00a0M, Choyke\u00a0PL, Shih\u00a0JH, Turkbey\u00a0B, Wood\u00a0BJ, Pinto\u00a0PA (2020) MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N\u00a0Engl J Med 382:917\u2013928. https:\/\/doi.org\/10.1056\/NEJMoa1910038","journal-title":"N Engl J Med"},{"key":"2738_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed\u00a0HU, El-Shater Bosaily\u00a0A, Brown\u00a0LC, Gabe\u00a0R, Kaplan\u00a0R, Parmar\u00a0MK, Collaco-Moraes\u00a0Y, Ward\u00a0K, Hindley\u00a0RG, Freeman\u00a0A, Kirkham\u00a0AP, Oldroyd\u00a0R, Parker\u00a0C, Emberton\u00a0M (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a\u00a0paired validating confirmatory study. Lancet 389:815\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet"},{"key":"2738_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/medicina57060519","volume":"57","author":"I Andras","year":"2021","unstructured":"Andras\u00a0I, Cata\u00a0ED, Serban\u00a0A, Kadula\u00a0P, Telecan\u00a0T, Buzoianu\u00a0M, Bungardean\u00a0M, Stanca\u00a0DV, Coman\u00a0I, Crisan\u00a0N (2021) Combined Systematic and MRI-US Fusion Prostate Biopsy Has the Highest Grading Accuracy When Compared to Final Pathology. Med (mex) 57:519. https:\/\/doi.org\/10.3390\/medicina57060519","journal-title":"Med (mex)"},{"key":"2738_CR4","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00345-019-02634-9","volume":"37","author":"R Diamand","year":"2019","unstructured":"Diamand\u00a0R, Oderda\u00a0M, Al Hajj Obeid\u00a0W, Albisinni\u00a0S, Van Velthoven\u00a0R, Fasolis\u00a0G, Simone\u00a0G, Ferriero\u00a0M, Roche\u00a0J\u2011B, Piechaud\u00a0T, Pastore\u00a0A, Carbone\u00a0A, Fiard\u00a0G, Descotes\u00a0J\u2011L, Marra\u00a0G, Gontero\u00a0P, Altobelli\u00a0E, Papalia\u00a0R, Kumar\u00a0P, Eldred-Evans\u00a0D, Giacobbe\u00a0A, Muto\u00a0G, Lacetera\u00a0V, Beatrici\u00a0V, Roumeguere\u00a0T, Peltier\u00a0A (2019) A multicentric study on accurate grading of prostate cancer with systematic and MRI\/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy. World J Urol 37:2109\u20132117. https:\/\/doi.org\/10.1007\/s00345-019-02634-9","journal-title":"World J Urol"},{"key":"2738_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012663.pub2","author":"Drost F-JH","year":"2019","unstructured":"Drost F\u2011JH, Osses\u00a0DF, Nieboer\u00a0D, Steyerberg\u00a0EW, Bangma\u00a0CH, Roobol\u00a0MJ, Schoots\u00a0IG (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD012663.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2738_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","volume":"385","author":"M Eklund","year":"2021","unstructured":"Eklund\u00a0M, J\u00e4derling\u00a0F, Discacciati\u00a0A, Bergman\u00a0M, Annerstedt\u00a0M, Aly\u00a0M, Glaessgen\u00a0A, Carlsson\u00a0S, Gr\u00f6nberg\u00a0H, Nordstr\u00f6m\u00a0T (2021) MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. N\u00a0Engl J Med 385:908\u2013920. https:\/\/doi.org\/10.1056\/NEJMoa2100852","journal-title":"N Engl J Med"},{"key":"2738_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein\u00a0JI, Egevad\u00a0L, Amin\u00a0MB, Delahunt\u00a0B, Srigley\u00a0JR, Humphrey\u00a0PA (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a\u00a0New Grading System. Am J Surg Pathol 40:244\u2013252. https:\/\/doi.org\/10.1097\/PAS.0000000000000530","journal-title":"Am J Surg Pathol"},{"key":"2738_CR8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay\u00a0J, Steliarova-Foucher\u00a0E, Lortet-Tieulent\u00a0J, Rosso\u00a0S, Coebergh\u00a0JWW, Comber\u00a0H, Forman\u00a0D, Bray\u00a0F (2013) Cancer incidence and mortality patterns in Europe: Estimates for 40\u00a0countries in 2012. Eur J Cancer 49:1374\u20131403. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.027","journal-title":"Eur J Cancer"},{"key":"2738_CR9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.29874","volume":"122","author":"CP Filson","year":"2016","unstructured":"Filson\u00a0CP, Natarajan\u00a0S, Margolis\u00a0DJA, Huang\u00a0J, Lieu\u00a0P, Dorey\u00a0FJ, Reiter\u00a0RE, Marks\u00a0LS (2016) Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer 122:884\u2013892. https:\/\/doi.org\/10.1002\/cncr.29874","journal-title":"Cancer"},{"key":"2738_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/21681805.2018.1438509","volume":"52","author":"A Fourcade","year":"2018","unstructured":"Fourcade\u00a0A, Payrard\u00a0C, Tissot\u00a0V, Perrouin-Verbe\u00a0M\u2011A, Demany\u00a0N, Serey-Effeil\u00a0S, Callerot\u00a0P, Coquet\u00a0J\u2011B, Doucet\u00a0L, Deruelle\u00a0C, Joulin\u00a0V, Nonent\u00a0M, Fournier\u00a0G, Valeri\u00a0A (2018) The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer. Scand J Urol 52:174\u2013179. https:\/\/doi.org\/10.1080\/21681805.2018.1438509","journal-title":"Scand J Urol"},{"key":"2738_CR11","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2147\/CMAR.S350701","volume":"14","author":"C Huang","year":"2022","unstructured":"Huang\u00a0C, Huang\u00a0Y, Pu\u00a0J, Xi\u00a0Q, Wei\u00a0X, Qiu\u00a0F, Wang\u00a0X, Zhao\u00a0X, Guo\u00a0L, Hou\u00a0J (2022) Comparison of MRI\/US Fusion Targeted Biopsy and Systematic Biopsy in Biopsy-Na\u00efve Prostate Patients with Elevated Prostate-Specific Antigen: A\u00a0Diagnostic Study. Cancer Manag Res 14:1395\u20131407. https:\/\/doi.org\/10.2147\/CMAR.S350701","journal-title":"Cancer Manag Res"},{"key":"2738_CR12","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan\u00a0V, Rannikko\u00a0AS, Borghi\u00a0M, Panebianco\u00a0V, Mynderse\u00a0LA, Vaarala\u00a0MH, Briganti\u00a0A, Bud\u00e4us\u00a0L, Hellawell\u00a0G, Hindley\u00a0RG, Roobol\u00a0MJ, Eggener\u00a0S, Ghei\u00a0M, Villers\u00a0A, Bladou\u00a0F, Villeirs\u00a0GM, Virdi\u00a0J, Boxler\u00a0S, Robert\u00a0G, Singh\u00a0PB, Venderink\u00a0W, Hadaschik\u00a0BA, Ruffion\u00a0A, Hu\u00a0JC, Margolis\u00a0D, Crouzet\u00a0S, Klotz\u00a0L, Taneja\u00a0SS, Pinto\u00a0P, Gill\u00a0I, Allen\u00a0C, Giganti\u00a0F, Freeman\u00a0A, Morris\u00a0S, Punwani\u00a0S, Williams\u00a0NR, Brew-Graves\u00a0C, Deeks\u00a0J, Takwoingi\u00a0Y, Emberton\u00a0M, Moore\u00a0CM (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N\u00a0Engl J Med 378:1767\u20131777. https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"2738_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance\u00a0W, Dreicer\u00a0R, Jarrard\u00a0DF, Scarpato\u00a0KR, Kim\u00a0SK, Kirkby\u00a0E, Buckley\u00a0DI, Griffin\u00a0JC, Cookson\u00a0MS (2023) Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023). J\u00a0Urol 209:1082\u20131090. https:\/\/doi.org\/10.1097\/JU.0000000000003452","journal-title":"J Urol"},{"key":"2738_CR14","doi-asserted-by":"publisher","first-page":"18910","DOI":"10.1038\/s41598-024-69804-7","volume":"14","author":"J Pensa","year":"2024","unstructured":"Pensa\u00a0J, Brisbane\u00a0W, Kinnaird\u00a0A, Kuppermann\u00a0D, Hughes\u00a0G, Ushko\u00a0D, Priester\u00a0A, Gonzalez\u00a0S, Reiter\u00a0R, Chin\u00a0A, Sisk\u00a0A, Felker\u00a0E, Marks\u00a0L, Geoghegan\u00a0R (2024) Evaluation of prostate cancer detection using micro-ultrasound versus MRI through co-registration to whole-mount pathology. Sci Rep 14:18910. https:\/\/doi.org\/10.1038\/s41598-024-69804-7","journal-title":"Sci Rep"},{"key":"2738_CR15","volume-title":"R: A\u00a0language and environment for statistical computing","author":"R Core Team","year":"2021","unstructured":"R Core Team (2021) R: A\u00a0language and environment for statistical computing"},{"key":"2738_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re\u00a0O, Puech\u00a0P, Renard-Penna\u00a0R, Claudon\u00a0M, Roy\u00a0C, M\u00e8ge-Lechevallier\u00a0F, Decaussin-Petrucci\u00a0M, Dubreuil-Chambardel\u00a0M, Magaud\u00a0L, Remontet\u00a0L, Ruffion\u00a0A, Colombel\u00a0M, Crouzet\u00a0S, Schott\u00a0A\u2011M, Lemaitre\u00a0L, Rabilloud\u00a0M, Grenier\u00a0N, Delongchamps\u00a0BN, Boutier\u00a0R, Bratan\u00a0F, Brunelle\u00a0S, Camparo\u00a0P, Colin\u00a0P, Corr\u00e9as\u00a0J\u2011M, Corn\u00e9lis\u00a0F, Cornud\u00a0F, Cros\u00a0F, Descotes\u00a0J\u2011L, Eschwege\u00a0P, Fiard\u00a0G, Fendler\u00a0J\u2011P, Habchi\u00a0H, Hallouin\u00a0P, Khairoune\u00a0A, Lang\u00a0H, Lebras\u00a0Y, Lef\u00e8vre\u00a0F, Malavaud\u00a0B, Moldovan\u00a0PC, Mottet\u00a0N, Mozer\u00a0P, Nevoux\u00a0P, Pagnoux\u00a0G, Pasticier\u00a0G, Portalez\u00a0D, Potiron\u00a0E, Thammavong\u00a0AS, Timsit\u00a0M\u2011O, Viller\u00a0A, Walz\u00a0J (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a\u00a0prospective, multicentre, paired diagnostic study. Lancet Oncol 20:100\u2013109. https:\/\/doi.org\/10.1016\/S1470-2045(18)30569-2","journal-title":"Lancet Oncol"},{"key":"2738_CR17","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha\u00a0M, Riet\u00a0K, Motloung\u00a0P, Gumenku\u00a0L, Adegoke\u00a0A, Mashele\u00a0S (2022) Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules 27:5730. https:\/\/doi.org\/10.3390\/molecules27175730","journal-title":"Molecules"},{"key":"2738_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel\u00a0RL, Giaquinto\u00a0AN, Jemal\u00a0A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"2738_CR19","unstructured":"The jamovi project (2025) jamovi"},{"key":"2738_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/a-0962-6489","volume":"50","author":"J Von Hardenberg","year":"2019","unstructured":"Von Hardenberg\u00a0J, Westhoff\u00a0N (2019) Prostatakarzinom: gezielte Fusionsbiopsie mit multiparametrischer MRT. Aktuelle Urol 50:473\u2013474. https:\/\/doi.org\/10.1055\/a-0962-6489","journal-title":"Aktuelle Urol"},{"key":"2738_CR21","unstructured":"(2024) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 7.0, AWMF-Registernummer: 043-022OL"},{"key":"2738_CR22","unstructured":"(2025) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 8.01, AWMF-Registernummer: 043-022OL"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02738-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02738-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02738-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:57:09Z","timestamp":1777460229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02738-8"}},"subtitle":["Wie verl\u00e4sslich ist das Biopsieergebnis?","How reliable are biopsy results?"],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2738"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02738-8","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.S. Merseburger macht folgende Angaben: Vortragshonorare: Ambu, Amgen, Apogepha, AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Farco, Ferring Ipsen, Hexal, Sandoz, MedUpdate, MSD, Merck Serono, Novartis, Janssen, Pfizer, Takeda, Novartis, Recordati und Roche. Beratert\u00e4tigkeit: Ambu, Amgen, Apogepha, AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Farco, Ferring Ipsen, Hexal, Sandoz, MedUpdate, MSD, Merck Serono, Novartis, Janssen, Pfizer, Takeda, Novartis, Recordati und Roche. Forschungsf\u00f6rderung und Studien: AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Ipsen, MSD, Merck Serono, Janssen, Pfizer, Takeda, Novartis, Recordati und Roche. H.E. Fender macht folgende Angaben: Merck, Corza medical, Viatris Healthcare GmbH, Bristol Myers Squibb. A. Moderegger macht folgende Angabe: Bristol Myers Squibb. P.\u00a0Schildhauer, M.\u00a0M\u00fcller, S.M.\u00a0Weiler, A.\u00a0F\u00fcrschke und Y.\u00a0Elser geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}